Pyronaridine tetraphosphate is primarily used as an antimalarial drug, particularly effective against Plasmodium falciparum, the parasite responsible for the most severe form of malaria. It is often combined with artesunate in artemisinin-based combination therapies (ACTs) to enhance efficacy and reduce the risk of drug resistance. This combination is widely utilized in regions where malaria is endemic, providing a critical treatment option for both uncomplicated and severe cases. Its mechanism involves interfering with the parasite's ability to detoxify heme, leading to its accumulation and subsequent death of the parasite. The drug is valued for its rapid action and ability to clear parasites from the bloodstream, contributing significantly to malaria control and eradication efforts globally.